Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports

Core Viewpoint - Zealand Pharma is ceasing the development of a potential next-generation obesity drug due to the conclusion that the market has become too crowded for the drug to differentiate itself [1] Company Summary - Zealand Pharma has decided to halt the development of its obesity drug, indicating a strategic shift in response to market conditions [1] Industry Summary - The obesity drug market is becoming increasingly competitive, leading to challenges for new entrants to establish a unique position [1]